Sergio Chimenti

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 790 citations · Full text

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris

Delano Pathirana, AD Ormerod, P. Saïag et al. · Journal of the European Academy of Dermatology and Venereology · 2009 · 695 citations · Full text

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2015 · 649 citations · Full text

Autoimmune Disease, Medicine, Phase Iii +7

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

Andrea Chiricozzi, Emma Guttman‐Yassky, Mayte Suárez‐Fariñas et al. · Journal of Investigative Dermatology · 2010 · 649 citations · Full text

Inflammation, Integrative Responses, Cytokine +13

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · The Lancet · 2015 · 388 citations · Full text

Autoimmune Disease, Clinical Trials, Inflammatory Marker +7